Cargando…

Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro

Major surgery induces systemic inflammation leading to pro-inflammatory activation of endothelial cells. Endothelial inflammation is one of the drivers of postoperative organ damage, including acute kidney injury Tumour Necrosis Factor alpha (TNF-α) is an important component of surgery-induced pro-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellermann, Sophie F., Jongman, Rianne M., Luxen, Matthijs, Kuiper, Timara, Plantinga, Josee, Moser, Jill, Scheeren, Thomas W. L., Theilmeier, Gregor, Molema, Grietje, Van Meurs, Matijs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750991/
https://www.ncbi.nlm.nih.gov/pubmed/36532777
http://dx.doi.org/10.3389/fphar.2022.992262
_version_ 1784850374631358464
author Ellermann, Sophie F.
Jongman, Rianne M.
Luxen, Matthijs
Kuiper, Timara
Plantinga, Josee
Moser, Jill
Scheeren, Thomas W. L.
Theilmeier, Gregor
Molema, Grietje
Van Meurs, Matijs
author_facet Ellermann, Sophie F.
Jongman, Rianne M.
Luxen, Matthijs
Kuiper, Timara
Plantinga, Josee
Moser, Jill
Scheeren, Thomas W. L.
Theilmeier, Gregor
Molema, Grietje
Van Meurs, Matijs
author_sort Ellermann, Sophie F.
collection PubMed
description Major surgery induces systemic inflammation leading to pro-inflammatory activation of endothelial cells. Endothelial inflammation is one of the drivers of postoperative organ damage, including acute kidney injury Tumour Necrosis Factor alpha (TNF-α) is an important component of surgery-induced pro-inflammatory activation of endothelial cells. Kinases, the backbone of signalling cascades, can be targeted by pharmacological inhibition. This is a promising treatment option to interfere with excessive endothelial inflammation. In this study, we identified activated kinases as potential therapeutic targets. These targets were pharmacologically inhibited to reduce TNF-α-induced pro-inflammatory signalling in endothelial cells. Kinome profiling using PamChip arrays identified 64 protein tyrosine kinases and 88 serine-threonine kinases, the activity of which was determined at various timepoints (5–240 min) following stimulation with 10 ng/ml TNF-α in Human umbilical vein endothelial cells in vitro. The PTKs Axl and Fyn were selected based on high kinase activity profiles. Co-localisation experiments with the endothelial-specific protein CD31 showed Axl expression in endothelial cells of glomeruli and Fyn in arterioles and glomeruli of both control and TNF-α-exposed mice. Pharmacological inhibition with Axl inhibitor BMS-777607 and Fyn inhibitor PP2 significantly reduced TNF-α-induced pro-inflammatory activation of E-selectin, VCAM-1, ICAM-1, IL-6 and IL-8 at mRNA and VCAM-1, ICAM-1, and IL-6 at protein level in HUVEC in vitro. Upon pharmacological inhibition with each inhibitor, leukocyte adhesion to HUVEC was also significantly reduced, however to a minor extent. In conclusion, pre-treatment of endothelial cells with kinase inhibitors BMS-777607 and PP2 reduces TNF-α-induced endothelial inflammation in vitro.
format Online
Article
Text
id pubmed-9750991
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97509912022-12-16 Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro Ellermann, Sophie F. Jongman, Rianne M. Luxen, Matthijs Kuiper, Timara Plantinga, Josee Moser, Jill Scheeren, Thomas W. L. Theilmeier, Gregor Molema, Grietje Van Meurs, Matijs Front Pharmacol Pharmacology Major surgery induces systemic inflammation leading to pro-inflammatory activation of endothelial cells. Endothelial inflammation is one of the drivers of postoperative organ damage, including acute kidney injury Tumour Necrosis Factor alpha (TNF-α) is an important component of surgery-induced pro-inflammatory activation of endothelial cells. Kinases, the backbone of signalling cascades, can be targeted by pharmacological inhibition. This is a promising treatment option to interfere with excessive endothelial inflammation. In this study, we identified activated kinases as potential therapeutic targets. These targets were pharmacologically inhibited to reduce TNF-α-induced pro-inflammatory signalling in endothelial cells. Kinome profiling using PamChip arrays identified 64 protein tyrosine kinases and 88 serine-threonine kinases, the activity of which was determined at various timepoints (5–240 min) following stimulation with 10 ng/ml TNF-α in Human umbilical vein endothelial cells in vitro. The PTKs Axl and Fyn were selected based on high kinase activity profiles. Co-localisation experiments with the endothelial-specific protein CD31 showed Axl expression in endothelial cells of glomeruli and Fyn in arterioles and glomeruli of both control and TNF-α-exposed mice. Pharmacological inhibition with Axl inhibitor BMS-777607 and Fyn inhibitor PP2 significantly reduced TNF-α-induced pro-inflammatory activation of E-selectin, VCAM-1, ICAM-1, IL-6 and IL-8 at mRNA and VCAM-1, ICAM-1, and IL-6 at protein level in HUVEC in vitro. Upon pharmacological inhibition with each inhibitor, leukocyte adhesion to HUVEC was also significantly reduced, however to a minor extent. In conclusion, pre-treatment of endothelial cells with kinase inhibitors BMS-777607 and PP2 reduces TNF-α-induced endothelial inflammation in vitro. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9750991/ /pubmed/36532777 http://dx.doi.org/10.3389/fphar.2022.992262 Text en Copyright © 2022 Ellermann, Jongman, Luxen, Kuiper, Plantinga, Moser, Scheeren, Theilmeier, Molema and Van Meurs. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ellermann, Sophie F.
Jongman, Rianne M.
Luxen, Matthijs
Kuiper, Timara
Plantinga, Josee
Moser, Jill
Scheeren, Thomas W. L.
Theilmeier, Gregor
Molema, Grietje
Van Meurs, Matijs
Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title_full Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title_fullStr Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title_full_unstemmed Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title_short Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
title_sort pharmacological inhibition of protein tyrosine kinases axl and fyn reduces tnf-α-induced endothelial inflammatory activation in vitro
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750991/
https://www.ncbi.nlm.nih.gov/pubmed/36532777
http://dx.doi.org/10.3389/fphar.2022.992262
work_keys_str_mv AT ellermannsophief pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT jongmanriannem pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT luxenmatthijs pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT kuipertimara pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT plantingajosee pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT moserjill pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT scheerenthomaswl pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT theilmeiergregor pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT molemagrietje pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro
AT vanmeursmatijs pharmacologicalinhibitionofproteintyrosinekinasesaxlandfynreducestnfainducedendothelialinflammatoryactivationinvitro